Autoimmune Encephalitis Panel Serum and CSF Test is a comprehensive diagnostic assessment aimed at detecting autoimmune disorders that affect the brain, leading to encephalitis. This condition is characterized by inflammation of the brain, which can result in a wide range of neurological symptoms such as cognitive impairment, seizures, and psychiatric manifestations. The test involves analyzing both serum (blood) and cerebrospinal fluid (CSF) samples to identify specific antibodies that target the central nervous system, indicating an autoimmune response.
The Autoimmune Encephalitis Panel is crucial for the accurate diagnosis and timely management of autoimmune encephalitis, facilitating the differentiation from other types of encephalitis and guiding appropriate treatment strategies. Conducted at DNA Labs UAE, a leading diagnostic facility known for its advanced testing capabilities and expertise in genetic and autoimmune disorders, this test ensures high precision and reliability.
The cost of the Autoimmune Encephalitis Panel Serum and CSF Test at DNA Labs UAE is set at 8190 AED. While the price might seem substantial, the comprehensive insights provided by this test are invaluable for patients experiencing symptoms of autoimmune encephalitis, offering a clear path towards effective treatment and management of the condition.
The HLA DSA-SAB Class I IgG Antibodies with C1q Screen Test is a specialized diagnostic procedure designed to identify specific antibodies in the human body that can play a crucial role in organ transplant compatibility and rejection. HLA stands for Human Leukocyte Antigen, a marker found on most cells in the body, which the immune system uses to recognize which cells belong in the body and which do not. DSA refers to Donor-Specific Antibodies, which are antibodies that develop against the antigens of the donor organ. The presence of these antibodies can lead to transplant rejection.
This test specifically targets Class I IgG antibodies, which are a type of antibody involved in the immune response, along with a C1q screen. The C1q component is part of the complement system, which helps antibodies clear pathogens from an organism. The C1q screen is used to determine if the detected antibodies are likely to activate the complement system, which can lead to a higher risk of organ rejection.
The test is available at DNA Labs UAE, a leading facility for genetic and specialized tests. The cost of the HLA DSA-SAB Class I IgG Antibodies with C1q Screen Test is 7960 AED. This test is particularly important for patients undergoing organ transplantation, as it helps in assessing the risk of transplant rejection and in managing post-transplant care to improve the chances of success and longevity of the transplant.
The Beta-2-Transferrin Fluid Test is a specialized diagnostic tool used primarily to detect the presence of cerebrospinal fluid (CSF) leaks. This test is particularly useful in cases where a CSF leak is suspected due to trauma, surgical procedures, or certain medical conditions affecting the skull or spine. Beta-2-Transferrin is a protein that is almost exclusively found in cerebrospinal fluid, making it a highly specific marker for identifying CSF leaks when detected in other bodily fluids such as nasal discharge.
The test is conducted by collecting a sample of the fluid suspected to contain CSF, which is then analyzed in a laboratory setting. The presence of Beta-2-Transferrin in the sample confirms the leakage of cerebrospinal fluid.
In the United Arab Emirates, this test is available at DNA Labs UAE, a reputable laboratory known for its advanced diagnostic services. The cost of the Beta-2-Transferrin Fluid Test at DNA Labs UAE is 7,720 AED. This price reflects the sophisticated nature of the test and the specialized expertise required to accurately detect and analyze the Beta-2-Transferrin protein. Patients seeking this test at DNA Labs UAE can expect high-quality service and reliable results, which are crucial for the appropriate management and treatment of conditions associated with CSF leaks.
The HLA DSA-SAB Class II IgG Antibodies with C1q Screen Test is a specialized diagnostic procedure aimed at identifying specific antibodies that can have a critical impact on organ transplant compatibility and success. HLA (Human Leukocyte Antigen) antibodies are part of the immune system's response to perceived foreign entities. The presence of these antibodies can indicate a potential for organ rejection in transplant scenarios.
This test specifically targets the Class II IgG antibodies. These antibodies are directed against the donor's HLA antigens, which can lead to complications in transplant recipients if not identified and managed properly. The inclusion of the C1q screen adds an additional layer of specificity by identifying antibodies capable of activating the complement system, which is a part of the immune system that enhances the ability of antibodies and phagocytic cells to clear pathogens from an organism. The activation of the complement system by these antibodies can lead to a higher risk of graft damage or loss.
Performed at DNA Labs UAE, a facility known for its advanced diagnostic technologies and expert staff, the test is priced at 7380 AED. Given the complexity and the specialized nature of the test, it represents a critical investment in the pre-transplant assessment process, helping to ensure that potential recipients have the highest chance of a successful transplant outcome by identifying and addressing immunological risks before they can impact the graft.
The AAAS Full Gene Sequence Analysis Allogrove Syndrome Test is a comprehensive diagnostic tool offered by DNA Labs UAE, designed to detect Alagille Syndrome, a genetic disorder that can affect the liver, heart, and other parts of the body. This test specifically targets the AAAS gene, mutations in which are known to be a significant cause of this condition. By sequencing the entire gene, the test can identify both known and novel mutations, providing crucial information for accurate diagnosis and management of the syndrome.
Priced at 7250 AED, the test is conducted in the state-of-the-art facilities of DNA Labs UAE, ensuring high-quality standards and reliable results. This test is particularly important for individuals with a family history of Alagille Syndrome or those exhibiting symptoms related to the disease, as it can guide treatment decisions and inform about the risk of passing the condition to future generations.
The Achondroplasia FGFR3 Full Gene Sequence Analysis Test is a specialized genetic test designed to identify mutations in the FGFR3 gene, which are responsible for achondroplasia, the most common form of dwarfism. This condition is characterized by a specific pattern of physical features and skeletal abnormalities, including shortened limbs and an enlarged head. The FGFR3 gene plays a crucial role in the development and maintenance of bone and tissue, and mutations in this gene disrupt normal growth patterns, leading to the characteristics associated with achondroplasia.
Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, the test involves analyzing the entire sequence of the FGFR3 gene to pinpoint any mutations. This comprehensive approach ensures high accuracy in diagnosis, which is critical for understanding the condition, guiding treatment decisions, and offering genetic counseling for families. The cost of the test is 6000 AED, reflecting the advanced technology and expertise required to perform this intricate analysis.
This test is particularly valuable for prospective parents with a family history of achondroplasia, couples seeking genetic counseling, and individuals displaying symptoms related to the condition. By confirming the presence or absence of FGFR3 gene mutations, the test provides essential information for managing health and making informed decisions about care and family planning.
The Endocrine Cancer Gene Panel Test, offered at DNA Labs UAE for a cost of 7200 AED, is a comprehensive diagnostic tool designed to identify genetic mutations associated with various types of endocrine cancers. This cutting-edge test analyzes multiple genes simultaneously, providing a detailed genetic profile that can help in the early detection, diagnosis, and management of endocrine cancers, including thyroid, adrenal, and pituitary tumors.
By focusing on specific gene mutations known to be linked with endocrine cancers, the test enables healthcare providers to tailor treatment strategies to the individual patient, potentially improving outcomes and reducing the risk of unnecessary treatments. The results from this panel can also offer valuable information regarding prognosis and the risk of cancer recurrence, as well as help in identifying at-risk family members who may benefit from genetic counseling and testing.
Conducted at the state-of-the-art facilities of DNA Labs UAE, the test ensures accuracy, confidentiality, and support from a team of genetic experts, making it a crucial resource for patients and doctors in the fight against endocrine cancers.
The Familial Mediterranean Fever (FMF) MEFV Full Gene Analysis Test is a comprehensive genetic screening designed to identify mutations in the MEFV gene, which are associated with Familial Mediterranean Fever. This condition is an inherited disorder that primarily affects individuals of Mediterranean and Middle Eastern descent, leading to recurrent fevers and painful inflammation of the abdomen, lungs, and joints. By analyzing the entire MEFV gene, this test can provide crucial information for the diagnosis, management, and treatment planning of FMF.
Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, the test ensures high accuracy and reliability in results. The cost of the FMF MEFV Full Gene Analysis Test is 7200 AED, reflecting the comprehensive nature of the genetic analysis and the expertise required to interpret its findings. This test is particularly important for individuals with a family history of FMF or those exhibiting symptoms, as early detection can significantly improve the quality of life through targeted treatments and lifestyle adjustments.
The Gastrointestinal Cancer Gene Panel Test is a sophisticated diagnostic tool designed to identify specific genetic mutations associated with various types of gastrointestinal cancers, including cancers of the stomach, colon, rectum, esophagus, and pancreas. By analyzing a patient's DNA, this comprehensive test can detect alterations in multiple genes that are known to increase the risk of developing gastrointestinal cancers.
Performed at DNA Labs UAE, a leading facility in genetic testing, the test offers a proactive approach for individuals with a family history of gastrointestinal cancers or those who want to assess their genetic predisposition to these diseases. The test cost is set at 7200 AED, reflecting the extensive analysis and detailed insights it provides. Results from this test can guide personalized prevention strategies, inform treatment decisions, and help in the early detection of cancers, significantly impacting patient outcomes.
The "Glioma Panel MGMT IDH1 and 2 FISH 1p19q Test" is a comprehensive diagnostic tool used in the field of oncology, specifically tailored for the assessment of gliomas, a type of tumor that occurs in the brain and spinal cord. This panel test is designed to analyze several genetic markers critical for the diagnosis, prognosis, and treatment planning of glioma cases.
The test focuses on the evaluation of:
- **MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation**: The methylation status of the MGMT gene is crucial for predicting the responsiveness of the tumor to alkylating agents, a common form of chemotherapy.
- **IDH1 and IDH2 mutations**: Mutations in the isocitrate dehydrogenase 1 and 2 genes are common in gliomas and are important prognostic factors. They can also influence treatment decisions.
- **FISH (Fluorescence In Situ Hybridization) for 1p19q co-deletion**: This test looks for the deletion of chromosomal arms 1p and 19q, which is associated with a better response to treatment and longer overall survival in patients with oligodendrogliomas, a subtype of glioma.
Conducted at DNA Labs UAE, a facility known for its advanced diagnostic technologies and expertise in genetic testing, this panel offers a crucial insight into the genetic makeup of gliomas. Understanding these genetic aspects allows healthcare providers to tailor a more effective and personalized treatment strategy for patients.
The cost of the Glioma Panel MGMT IDH1 and 2 FISH 1p19q Test is 7200 AED. Given the detailed genetic insights it provides, this test is a valuable investment for patients undergoing glioma treatment, potentially leading to more targeted therapies with better outcomes.
